YishengBio Co., Ltd (YishengBio) has completed its business combination with Summit Healthcare Acquisition Corp. recently and went public on NASDAQ via the De-SPAC route on March 17, 2023. EST. YS Biopharma remains as the combined company and commenced trading on the NASDAQ Capital Market, with its ordinary shares and warrants listed under the new Stock Codes YS and YSBPW, respectively.

As the Chinese legal adviser to YishengBio, Jingtian & Gongcheng’s legal team provided professional and efficient legal services throughout the De-SPAC transaction, including assisting the company in designing the offshore transaction structure, reviewing transaction documents and preparing the disclosure letter, conducting Chinese legal due diligence, compiling disclosures related to Chinese laws in Form F-4, and answering inquiries from the regulator, which were highly recognized by the client and the intermediary team.